Pulmonx Corporation to Host Fireside Chat at Major Conference
Pulmonx Corporation (Nasdaq: LUNG) is excited to announce its upcoming participation in a fireside chat at a prestigious healthcare conference. This significant event takes place at the Piper Sandler 36th Annual Healthcare Conference, scheduled for a Wednesday in December.
Details of the Conference Participation
The presentation will occur at 9:30 AM PT / 12:30 PM ET. Pulmonx invites everyone interested in the latest developments in minimally invasive treatments for severe lung diseases to join. The company will share insights into their innovative approaches that aim to improve the quality of life for patients suffering from chronic obstructive pulmonary disease (COPD).
Accessible Presentation via Webcast
For those unable to attend in person, the company will facilitate a live and archived webcast of the fireside chat. Pulmonx encourages individuals to visit the Investors section on their official website where the webcast will be hosted. It’s a wonderful opportunity to gain knowledge about the latest advancements in pulmonary therapy from a recognized leader in the field.
Pioneering Solutions for Lung Health
Pulmonx Corporation specializes in revolutionary treatments tailored for patients who suffer from severe emphysema and COPD. Their flagship product, the Zephyr Endobronchial Valve, has received recognition as a breakthrough device by regulatory authorities. It is designed to provide significant relief for patients who continue to experience debilitating symptoms despite traditional medical interventions.
Innovative Products and their Impact
Pulmonx's offerings, including the Chartis Pulmonary Assessment System and the LungTraX Platform, are vital tools that serve to accurately assess patient conditions. These products not only enhance the quality of diagnoses but also streamline treatment processes, allowing healthcare providers to deliver personalized care effectively.
Global Reach and Recognition
With the Zephyr Valve approved for commercialization in over 25 countries, it has established itself globally as a standard of care for treating severe emphysema. Numerous clinical guidelines advocate for its use, further solidifying Pulmonx's commitment to enhancing patient outcomes and experiences.
About Pulmonx Corporation
Aiming to change lives, Pulmonx Corporation has made significant strides in the field of pulmonary treatments. By addressing the urgent need for effective solutions against severe lung diseases, the company remains dedicated to research, development, and patient-centric care.
Connect with Pulmonx
For those who wish to delve deeper into Pulmonx’s innovative offerings or inquire about the company, reaching out is easy. Contact Brian Johnston at Gilmartin Group via email for any investor-related questions.
Frequently Asked Questions
What is the focus of Pulmonx Corporation?
Pulmonx Corporation specializes in minimally invasive treatments aimed at severe lung diseases, particularly COPD and emphysema.
When will Pulmonx present at the Piper Sandler Healthcare Conference?
The company will present during a fireside chat scheduled for a Wednesday in December.
How can I access the conference presentation if I can't attend?
A live and archived webcast of the presentation will be available on Pulmonx’s official website under the Investors section.
What is the significance of the Zephyr Valve?
The Zephyr Endobronchial Valve is a breakthrough device designed to alleviate symptoms for patients suffering from severe emphysema, improving their quality of life.
How can I contact Pulmonx for more information?
For inquiries, reach out to Brian Johnston at Gilmartin Group via the investor email address provided.